Meeting
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
Authors
Jiayong Liu
Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital, Beijing, China
Jiayong Liu , Tian Gao , Qiuzhong Pan , Chujie Bai , Zhaosheng Han , Zhichao Tan , Ruiqing Peng , Bushu Xu , Xizhi Wen , Huafang Cen , Chaoxian Yan , Johnson Yiu-Nam Lau , Lun Zeng , Xueyun Wu , Yusheng Ou , Haiping Gong , Yingjie Huang , Zhengfu Fan , Xing Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT05549921
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11548)
DOI
10.1200/JCO.2024.42.16_suppl.11548
Abstract #
11548
Poster Bd #
474
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.
First Author: Aaron Rapoport
Poster
2017 ASCO Annual Meeting
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
First Author: Ben C. Creelan
Poster
2023 ASCO Annual Meeting
Results from phase I/II study of NY-ESO-1-specific TCR gene-transduced T cell therapy (TBI-1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma.
First Author: Akira Kawai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
First Author: E. Gabriela Chiorean